Edition:
United States

Mylan NV (MYL.OQ)

MYL.OQ on NASDAQ Stock Exchange Global Select Market

35.01USD
12:25pm EST
Change (% chg)

$0.51 (+1.48%)
Prev Close
$34.50
Open
$34.50
Day's High
$35.07
Day's Low
$34.25
Volume
763,808
Avg. Vol
2,122,783
52-wk High
$55.50
52-wk Low
$33.60

MYL.OQ

Chart for MYL.OQ

About

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty. Its Generics segment... (more)

Overall

Beta: 1.07
Market Cap(Mil.): $18,461.13
Shares Outstanding(Mil.): 535.11
Dividend: --
Yield (%): --

Financials

  MYL.OQ Industry Sector
P/E (TTM): 67.59 30.04 30.65
EPS (TTM): 0.51 -- --
ROI: 1.15 15.86 15.23
ROE: 2.38 16.96 16.56

EpiPen maker Mylan to restructure, cut workforce

Generic drugmaker Mylan NV , which has been under fire for price hikes on the life-saving EpiPen allergy treatment, said on Wednesday that it expected to cut less than 10 percent of its workforce in a restructuring to integrate acquisitions.

Dec 07 2016

BRIEF-Mylan NV enters into a revolving credit agreement

* Mylan NV says on November 22, 2016, entered into a revolving credit agreement

Nov 29 2016

Senate panel postpones Mylan hearing

WASHINGTON The U.S. Senate Judiciary Committee on Monday postponed a hearing planned for next week to discuss Mylan NV's pending $465 million settlement to resolve charges that it underpaid government healthcare programs by misclassifying its EpiPen emergency allergy treatment.

Nov 24 2016

Mylan declines Senate committee request to testify about EpiPen

Mylan NV has declined a U.S. Senate committee request to testify about a $465 million pending settlement to resolve charges the company underpaid government healthcare programs by misclassifying its the EpiPen emergency allergy treatment.

Nov 21 2016

Mylan declines Senate committee request to testify about EpiPen

Nov 21 Mylan NV has declined a U.S. Senate committee request to testify about a $465 million pending settlement to resolve charges the company underpaid government healthcare programs by misclassifying its the EpiPen emergency allergy treatment.

Nov 21 2016

BRIEF-U.S. senator Chuck Grassley says Mylan declining to testify at judiciary committee hearing

* Says Mylan declining to testify at judiciary committee hearing on potential settlement between Mylan and DOJ Source text - (http://bit.ly/2fy1MoP) Further company coverage:

Nov 21 2016

Corporates stay strong despite market rout

LONDON, Nov 21 (IFR) - Corporate borrowers on both sides of the Atlantic shrugged off concerns about global volatility last week with pharmaceutical companies leading the charge, although they had to pay significantly higher premiums.

Nov 21 2016

BRIEF-Greenlight Capital ups stake in Mylan, cuts in GM

* Ups share stake in Mylan NV by 29.4 percent to 6.4 million shares - SEC filing

Nov 14 2016

US pharmas eye Europe's bond market amid rates volatility

LONDON, Nov 14 (IFR) - US pharmaceuticals AbbVie and Mylan have set their sights on Europe's bond market to sell debut euro bonds, taking advantage of positive sentiment for the sector after last week's unexpected Donald Trump victory in the US election.

Nov 14 2016

Perrigo to review options for Multiple Sclerosis drug Tysabri

Perrigo Co Plc reported a higher-than-expected adjusted quarterly profit and said it would review strategic options for royalty rights from sales of multiple sclerosis drug Tysabri.

Nov 10 2016

Earnings vs. Estimates